LIGAND PHARMACEUTICALS
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified,... and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.
LIGAND PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1987-09-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ligand.com
Total Employee:
101+
Status:
Active
Contact:
858-550-7500
Email Addresses:
[email protected]
Total Funding:
875 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Microsoft Exchange Online
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-09-10 | xCella Biosciences | xCella Biosciences acquired by Ligand Pharmaceuticals | 7 M USD |
| 2020-09-10 | Taurus Biosciences | Taurus Biosciences acquired by Ligand Pharmaceuticals | 5 M USD |
| 2020-08-10 | Pfenex | Pfenex acquired by Ligand Pharmaceuticals | 438 M USD |
| 2020-02-11 | Icagen - Core Assets, Partnered Programs And ION Channel Technologies | Icagen - Core Assets, Partnered Programs And ION Channel Technologies acquired by Ligand Pharmaceuticals | 15 M USD |
| 2019-07-23 | Ab Initio Biotherapeutics | Ab Initio Biotherapeutics acquired by Ligand Pharmaceuticals | 12 M USD |
| 2018-08-09 | Vernalis | Vernalis acquired by Ligand Pharmaceuticals | 43 M USD |
| 2017-10-04 | Crystal Bioscience | Crystal Bioscience acquired by Ligand Pharmaceuticals | 35.5 M USD |
| 2015-12-18 | OMT | OMT acquired by Ligand Pharmaceuticals | 178 M USD |
| 2015-05-11 | Selexis | Selexis acquired by Ligand Pharmaceuticals | 4 M USD |
| 2011-01-27 | CyDex Pharmaceuticals | CyDex Pharmaceuticals acquired by Ligand Pharmaceuticals | N/A |
Investors List
Venrock
Venrock investment in Seed Round - Ligand Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-05-28 | Palvella Therapeutics | Ligand Pharmaceuticals investment in Series C - Palvella Therapeutics | 45 M USD |
| 2019-02-05 | Dianomi Therapeutics | Ligand Pharmaceuticals investment in Corporate Round - Dianomi Therapeutics | 3 M USD |
| 2018-12-18 | Palvella Therapeutics | Ligand Pharmaceuticals investment in Corporate Round - Palvella Therapeutics | 10 M USD |
| 2014-05-26 | Viking Therapeutics | Ligand Pharmaceuticals investment in Debt Financing - Viking Therapeutics | 2.5 M USD |
Official Site Inspections
http://www.ligand.com Semrush global rank: 2.67 M Semrush visits lastest month: 6.27 K
- Host name: 104.21.89.4
- IP address: 104.21.89.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
